Advancing a promising treatment for retinitis pigmentosa
Location: United States, Texas, Fort Worth
Employees: 11-50
Total raised: $16.5M
Founded date: 2016
Investors 2
| Date | Name | Website |
| 07.05.2025 | Johns Hopk... | ventures.j... |
| - | Retinal De... | retinaldeg... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.06.2022 | Series B | $16.5M | - |
Mentions in press and media 2
| Date | Title | Description |
| 17.06.2022 | Nacuity Pharmaceuticals Raises $16.5M in Series B Financing | Nacuity Pharmaceuticals, Inc., a Fort Worth, Texas-based clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, closed a $16.5m Series B finan... |
| 31.03.2021 | Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates | Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates Wed, Mar 31, 2021 07:10 CET Press release Nanoform Finland Plc March 31, 2021 08:10 a.m. Finnish time / 07:10 a.m. Sw... |